文献速递慢性静脉疾病

Zylox Penguin与Zilver Vena支架治疗非血栓性髂静脉病变的多中心随机对照试验比较

Comparison of the Zylox Penguin Venous Stent System and Zilver Vena Stent for Non-thrombotic Iliac Vein Lesions: A Multicentre Randomised Controlled Trial.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2026-02-25

本研究为多中心随机对照试验,纳入161例非血栓性髂静脉病变患者,比较Zylox Penguin与Zilver Vena支架的安全性和疗效。主要终点12个月一期通畅率分别为98%和90%,绝对风险差7.5%(95%CI -0.1-16.6%),Zylox Penguin达到非劣效终点(p=.069)。两组临床症状和生活质量均显著改善。

要点

  • Zylox Penguin支架12个月一期通畅率98%,Zilver Vena为90%,达到非劣效终点。
  • 两组MLD、靶病变血运重建率、器械置入成功率及手术成功率无显著差异。
  • Zylox Penguin组12个月髂静脉直径狭窄程度显著更低(17.6±10.0% vs 23.2±15.7%,p=.010)。

核心结论

  • Zylox Penguin静脉支架系统治疗非血栓性髂静脉病变安全有效,可显著缓解临床症状并改善生活质量。

研究设计与样本

  • 多中心随机对照试验(NCT04812444),纳入14家中国医院的161例非血栓性髂静脉病变患者,随机分配至Zylox Penguin组或Zilver Vena组。

主要发现

  • 12个月一期通畅率Zylox Penguin组为98%,Zilver Vena组为90%,绝对风险差7.5%(95%CI -0.1-16.6%),达到非劣效终点(p=.069)。
  • 12个月时Zylox Penguin组髂静脉直径狭窄程度(17.6±10.0%)显著低于Zilver Vena组(23.2±15.7%)(p=.010)。
  • 两组VCSS变化分别为-5和-6,CIVIQ-14变化均为-7,较基线均显著改善(均p<.001)。
  • 12个月时水肿消退率分别为28%和29%(p=.92),基线C6患者溃疡愈合率分别为85%和82%(p=.85)。

关键数值与推荐

  • 主要终点为12个月一期通畅率,非劣效性检验p=.069。
  • Zylox Penguin组12个月髂静脉直径狭窄程度17.6±10.0%,Zilver Vena组23.2±15.7%(p=.010)。
  • VCSS变化:Zylox Penguin组-5,Zilver Vena组-6;CIVIQ-14变化两组均为-7(均p<.001)。
  • 水肿消退率:Zylox Penguin组28%,Zilver Vena组29%(p=.92);C6患者溃疡愈合率:85% vs 82%(p=.85)。

临床怎么用

  • 对于非血栓性髂静脉病变,Zylox Penguin支架可作为安全有效的选择,其12个月通畅率非劣于Zilver Vena支架。
  • Zylox Penguin支架在降低髂静脉直径狭窄程度方面可能更具优势,但需结合个体情况选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to evaluate the safety, efficacy, and associated complications of the Zylox Penguin venous stent system vs. the Zilver Vena stent for treating non-thrombotic iliac vein lesions (NIVLs) through a multicentre randomised controlled trial (NCT04812444). METHODS: Patients with NIVLs were assigned randomly to either the Zylox Penguin stent group or the Zilver Vena stent group to assess treatment efficacy. The primary outcome was 12 month primary patency. Secondary outcomes included minimum luminal diameter (MLD), degree of diameter stenosis, target vein revascularisation rate at 12 months, device placement success, procedural success, and improvement of Venous Clinical Severity Score (VCSS), Clinical-Etiology-Anatomy-Pathophysiology (CEAP) classification, and Chronic Venous Disease Quality of Life Questionnaire 14 (CIVIQ-14). RESULTS: The study recruited 161 patients from 14 Chinese hospitals. The 12 month primary patency rate was 98% for the Zylox Penguin stent and 90% for the Zilver Vena stent, with an absolute risk difference of 7.5% (95% confidence interval -0.1 - 16.6%). The Zylox Penguin met the non-inferiority endpoint (p = .069). No significant differences were observed in MLD, degree of iliac vein stenosis, or rates of target lesion revascularisation, device placement success, or procedural success. The Zylox Penguin stent group showed a significantly lower degree of iliac vein diameter stenosis (17.6 ± 10.0%) than the Zilver Vena stent group (23.2 ± 15.7%) at 12 months (p = .010). VCSS changes were -5 and -6 for the Zylox Penguin and Zilver Vena stent groups, respectively, while CIVIQ-14 changes were -7 for both groups at 12 months, showing statistically significant improvements compared with baseline (both p < .001). At 12 months post-procedure, oedema resolution occurred in 28% and 29% of all Zylox and Zilver patients, respectively (p = .92), with 85% and 82% of baseline C6 patients showing ulcer healing (p = .85). CONCLUSION: The Zylox Penguin venous stent system is safe and effective for treating NIVLs, significantly relieving clinical symptoms and improving quality of life.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Liu H, Zeng Q, Li F, et al. Comparison of the Zylox Penguin Venous Stent System and Zilver Vena Stent for Non-thrombotic Iliac Vein Lesions: A Multicentre Randomised Controlled Trial. Eur J Vasc Endovasc Surg. 2026. PMID: 41759711. doi:10.1016/j.ejvs.2026.02.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。